500 Unicorn Park Drive
Suite 303
Woburn, MA 01801
United States
781 222 9600
https://www.replimune.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 284
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Philip Astley-Sparke F.S.A. | Executive Chairman | 1.07M | N/A | 1971 |
Dr. Sushil Patel Ph.D. | Chief Executive Officer | 665.05k | N/A | 1971 |
Dr. Robert Coffin Ph.D. | Founder, Chief Scientist & Director | 785.89k | N/A | 1965 |
Ms. Emily Luisa Hill | Chief Financial Officer | N/A | N/A | 1980 |
Mr. Andrew Schwendenman | Chief Accounting Officer & Treasurer | N/A | N/A | 1976 |
Mr. Christopher Sarchi | Chief Commercial Officer | N/A | N/A | 1968 |
Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. | Chief Medical Officer | N/A | N/A | 1966 |
Mr. Paul Bullock | Chief Manufacturing Officer & Framingham Site Head | N/A | N/A | N/A |
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Replimune Group, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 7; Board: 6; Shareholder Rights: 8; Compensation: 8.